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Abstract
Background: Human milk is recommended for very preterm infants, but its variable macronutrient content may
contribute to undernutrition during a critical period in development. We hypothesize that individually targeted
human milk fortification is more effective in meeting macronutrient requirements than the current standard of care.
Methods: We designed a single-center randomized, controlled trial enrolling 130 infants born < 31 completed
weeks’ gestation. Participants will receive fortified maternal and/or pasteurized donor milk but no formula. For
participants in the intervention group, milk will be individually fortified with protein and fat modulars to achieve
target levels based on daily point-of-care milk analysis with mid-infrared spectroscopy, in addition to standard
fortification. The study diet will continue through 36 weeks’ postmenstrual age (PMA). Clinical staff and parents will
be masked to study group. Primary outcomes include: 1) body length and lean body mass by air displacement
plethysmography at 36 weeks’ PMA; 2) quantitative magnetic resonance imaging-based measures of brain size and
microstructure at term equivalent age; and 3) Bayley-IV scales at 2 years’ corrected age.
Discussion: We expect this trial to provide important data regarding the effectiveness of individually targeted
human milk fortification in the neonatal intensive care unit (NICU).
Trial registration: NCT03977259, registered 6 June, 2019.
Keywords: Human milk, Nutrition, Very preterm infant, Neonatal intensive care, Growth, Neurodevelopment,
Magnetic resonance imaging, Randomized trial
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Background
For hospitalized very preterm infants, the two to 4
month-long neonatal intensive care unit (NICU)
hospitalization coincides with a critical period in devel-
opment during which the brain is uniquely sensitive to
nutrition [1, 2]. The use of human milk is recommended
based on strong evidence of short- and long-term bene-
fits [3, 4]. Aiming to support fetal rates of physical
growth and tissue accretion [5–7], multi-component hu-
man milk fortification is recommended [8, 9] and prac-
ticed widely [10]. However, epidemiologic data indicate
that NICU growth outcomes remain far short of the goal
to match in-utero growth [11, 12]. Additionally, we and
others have reported slower weight gain and head cir-
cumference growth among fortified human milk-fed as
compared with preterm formula-fed infants [13–17],
suggesting gaps in current fortification strategies. These
gaps are particularly relevant given the recent rise in the
use of both maternal and donor milk NICUs [18].
A major challenge in clinical care is that in prescribing
nutritional interventions, NICU clinicians rely on pub-
lished average nutrient values [5, 9] whereas the actual
macronutrient content of human milk varies consider-
ably [19]. Pasteurized donor milk is also variable and is,
on average, lower in protein content than maternal milk
[20, 21]. Thus, over time, and despite standard fortifica-
tion, some preterm infants may accumulate protein and/
or energy deficits that adversely impact their physical
growth and/or brain development, with likely implica-
tions for long-term neurodevelopmental outcomes.
The recent availability of a reliable point-of-care hu-
man milk analyzer provides an opportunity to individu-
ally target fortification of human milk in the NICU.
However, only a few randomized trials have examined
the effectiveness of this approach in improving physical
growth [22], and the results have been inconsistent.
Additionally, virtually no data exist on outcomes beyond
NICU discharge, and effects of an individualized ap-
proach to human milk fortification on structural brain
development during the neonatal period are unknown.
To address these knowledge gaps, we designed Nour-
ish as a single-center randomized, controlled clinical
trial designed with the aim of evaluating the effective-
ness of individually targeted human milk fortification, as
compared with standard-of-care fortification, in promot-
ing physical growth, structural brain development, and
neurodevelopmental outcomes in very preterm infants.
Primary outcome domains for Nourish are: 1) physical
growth during the intervention; 2) magnetic resonance
imaging (MRI) based measures of brain development at
term equivalent age; and 3) neurodevelopmental out-
comes at 2 years’ corrected age. The overall hypothesis is
that minimizing protein and energy deficits by individu-
ally targeting human milk fortification during the NICU
hospitalization will improve physical growth, regional
brain development, and neurodevelopmental function.
Methods / design
Setting and eligibility criteria
This randomized clinical trial will take place at Brigham
and Women’s Hospital, an academic Level III NICU in
Boston, MA. Inclusion criteria are: 1) singleton or twin
infant with gestational age at birth 24 0/7 to 30 6/7
weeks; 2) chronologic age < 21 days; and 3) mother pro-
viding milk, with clinical consent given to use pasteur-
ized donor human milk if maternal milk is in short
supply or unavailable. Exclusion criteria include: 1)
major congenital anomaly; 2) birth weight < 3rd percent-
ile [23]; 3) necrotizing enterocolitis or other clinically
significant gastrointestinal pathology; 4) clinically signifi-
cant renal or hepatic dysfunction or inborn error of me-
tabolism; 5) fluid restriction < 140mL/kg/day anticipated
for 3 or more days; 6) grade 3 or 4 intraventricular
hemorrhage detected prior to enrollment; and 7) antici-
pated transfer < 36 weeks’ postmenstrual age or expected
death.
Informed consent
Written, informed consent from one parent will be ob-
tained by a research nurse, dietitian, or physician. Con-
sent documents will be available in English and Spanish
and will cover both clinical trial participation and the
use of data and/or bio-specimens for future research.
Separate consent forms will be used for the NICU and
follow-up phases. This study protocol (2019P000893)
was approved by the Partners Human Research Commit-
tee (FWA00000484) on June 25, 2019.
Milk collection, pooling, and analysis
As soon as possible after delivery, mothers of all preterm
infants admitted to the NICU receive standard written
and verbal instructions by a board-certified lactation
consultant to express milk at least 8 times per day with
a double-electric breast pump, augmented with hand ex-
pression to improve emptying. For enrolled infants dur-
ing the study diet period, each weekday, research
assistants will pool fresh maternal milk and supplement
with frozen maternal milk and/or donor milk as needed
based on the daily volume ordered by the clinical team
(typically 150–160 mL/kg/day). From these 24-h pools,
3 mL of milk will be sonicated for 5 s and warmed to
40 °C using a bead warmer, then analyzed for macronu-
trient content with a mid-infrared spectroscopy-based
human milk analyzer (sonicator, bead warmer, and
analyzer all Miris AB, Uppsala, Sweden) [24]. Each sam-
ple of milk will be analyzed once.
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Intervention
The study period will start the first weekday that the in-
fant reaches the clinical standard goal human milk diet,
defined as ≥140 mL/kg/day fortified with multicompo-
nent liquid human milk fortifier (Similac human milk
fortifier hydrolyzed protein concentrated liquid, Abbott
Laboratories, 5 mL added to 25 mL milk, equivalent to
24 kcal/ounce assuming the ‘base’ milk is 20 kcal/oz)
plus liquid protein fortifier (Abbott Laboratories) at 0.27
g/dL (“Step 1” assuming that the ‘base’ milk contains 1
g/dL protein, with the goal to provide ≥4 g/kg/day pro-
tein) and is not receiving IV fluids. Throughout the trial,
if maternal milk is in short supply or not available, pas-
teurized donor human milk (“donor milk”) will be used.
To reduce variability of donor milk macronutrient com-
position, particularly of protein which declines with ad-
vancing lactation duration [21], we will use pasteurized
milk that was expressed within 3 months of delivery,
provided by a community-based milk bank affiliated with
the Human Milk Banking Association of North America
(Mother’s Milk Bank Northeast, Newton MA). Infant
formula will not be used for supplementation during the
study period. Routine electrolyte monitoring and supple-
mentation and supplementation of Vitamin D and iron
for all participants will follow a local Enteral Nutrition
Clinical Guideline, available upon request.
In addition to the standard-of-care diet of human milk
(maternal and/or donor) with multi-component HMF to
24 kcal/oz. and “Step 1” protein, milk for infants in the
intervention group will be additionally fortified with li-
quid protein (Abbott Laboratories) and/or medium
chain triglyceride (MCT) oil (Dot Foods, Nestle USA) to
ensure target levels in the ‘base’ milk of 1 g/dL for pro-
tein and 3.9 g/dL for fat (Fig. 1). Individual recipes are
calculated in a custom-built Excel spreadsheet based on
data input including the infant’s body weight, daily fluid
volume, and milk macronutrients. Currently, we do not
have access to a sterile carbohydrate modular, which
means that even after target levels of protein and fat are
reached, the energy content may remain below the target
of 67.7 kcal/dL. Should energy content fall below this
target, we will add more MCT oil to achieve the energy
target. We will use the following formula to calculate
the energy content of milk: 9*fat + 4*protein + 4*carbo-
hydrate [25] with fat, protein, and carbohydrate values
taken from the milk analysis. We will use the “true pro-
tein” value (crude protein*0.8) to account for non-
protein nitrogen [24].
Management of growth faltering
Growth faltering is defined as an average weight gain <
15 g/kg/day or gain in body length < 0.8 cm per week.
Management of growth faltering among participants will
proceed as follows: 1) increase enteral feeding volume by
10mL/kg/day, if acceptable to the clinical team; 2) add
MCT oil to increase energy density to 26 kcal/oz. based
on assumed ‘base’ milk energy content of 20 kcal/oz.; 3)
increase standard liquid protein fortifier to 0.54 g/dL
(“Step 2”); and 4) further increase standard energy dens-
ity to 28 kcal/oz. with MCT oil and/or increase protein
to 0.8 g/dL (“Step 3”).
Criteria for discontinuing or modifying allocated
interventions
If growth faltering persists despite taking the above
steps, partial formula supplementation will be consid-
ered by the clinical and research teams. Participants will
be removed from the study if they develop NEC or any
other exclusion criteria, or at parent request.
Outcomes
We will assess physical growth with 1) anthropom-
etry and 2) body composition analysis. At study start
and end points, we will weigh infants in duplicate on
a calibrated portable digital scale; if the infant is not
Fig. 1 Schematic of standard fortification and individually targeted
fortification in the Nourish study. Standard fortification will be
provided for all participants and comprises 1) multicomponent
liquid human milk fortifier (Similac human milk fortifier hydrolyzed
protein concentrated liquid, Abbott Laboratories), 5 mL added to 25
mL milk and 2) liquid protein fortifier (Abbott Laboratories) at 0.27 g/
dL. Milk for infants in the intervention group will also be individually
fortified with liquid protein (Abbott Laboratories) and/or medium
chain triglyceride (MCT) oil (Dot Foods, Nestle USA) to ensure target
levels in the ‘base’ milk of 1 g/dL for protein, 3.9 g/dL for fat, and
67.7 kcal/dL for energy. If maternal milk is in short supply,
pasteurized donor milk expressed within 3 months of delivery will
be used. The study diet will continue through 36 weeks’
postmenstrual age
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stable enough to be weighed on a portable scale, we
will use the built-in isolette scale. Body length will
be measured in duplicate with a recumbent length
board and head circumference with a non-stretchable
tape and both recorded to 0.1 cm. One of two regis-
tered neonatal dietitians will perform all anthropo-
metric measurements, assisted by a trained research
assistant and with other clinical assistance (e.g. bed-
side nurse, respiratory therapist) as indicated. Interra-
ter reliability between the 2 dietitians will be
assessed at baseline and quarterly throughout the
study period. We will use an infant air displacement
plethysmography system (PEA POD, Cosmed, Con-
cord CA) to measure infant body volume and mass
and estimate fat mass and fat free mass with a 2-
compartment model [26]. Infants will undergo body
composition assessment as soon as possible upon
study start, with timing based on the ability to re-
main off respiratory support during the assessment,
and again at study end point.
We will assess structural brain development with MRI.
Infants will be scanned without sedation at term equiva-
lent age (38–41 weeks’ postmenstrual age, PMA) using a
“feed and wrap” method [27]. We will use a 3 Tesla
Prisma system (Siemens) equipped with a 16-channel
pediatric head coil. To derive the primary volumetric
outcomes (total brain volume, cerebellar volume), we
will use an automated segmentation method, MANTiS
[28]. A secondary MRI outcome will be fractional anisot-
ropy in the posterior limb of the internal capsule (PLIC),
a measure of white matter microstructure. We will
manually delineate the PLIC using region-of-interest
based analysis [29].
To assess neurodevelopment at 2 years’ corrected age,
we will use the Bayley Scales of Infant and Toddler De-
velopment, 4th edition [30]. Primary outcomes will in-
clude the cognitive and motor scores (continuous).
Secondary outcomes will include cognitive and motor
delay (scores < 85) and the language score (continuous
and < 85). We will assess spatial working memory with
the “Spin the Pots” task, [31] behavioral inhibition with
the “Mommies and Babies” task, [32] and executive
function and behavioral difficulties using valid parent
questionnaires [33, 34]. At 2 years, we will reassess an-
thropometry using similar methods to those described
previously, and assess blood pressure with an automated
oscillometric device.
To promote cohort retention and collect interim
data on infant development, we will administer ma-
ternal questionnaires at 4 and 12 months’ corrected
age, including the Baby Pediatric Symptom Checklist,
Motor and Social Development Scale, [35] Ages and
Stages, [36] and Infant Toddler Quality of Life scale
[37].
Participant timeline
The timeline of enrollment, interventions, and assess-
ments are shown in Fig. 2.
Sample size
The planned sample size is 130 infants (65 per study
group). Accounting for expected attrition (5% by NICU
discharge due to death or unexpected transfer) and an
additional 5% loss due to uncorrectable motion artifact
for MRI outcomes, we expect to be able to detect a
moderate effect of the intervention on primary outcomes
(0.49 z-scores in weight, 0.24 z-scores in fat free mass,
24 cc total brain volume) at α = 0.05 and power 0.8. Ac-
counting for 10% further attrition to 2 years’ corrected
age, we have adequate power to detect an 8.1-point dif-
ference between groups on the Bayley cognitive scale.
Assignment of interventions
We will use permuted block randomization and assign
participants 1:1 to the standard of care diet (control) or
individually fortified diet (intervention). Twins will be
randomized individually. The study biostatistician will
generate the allocation sequence and place the assign-
ments in envelopes, to be opened by the research assis-
tants on the study start date.
Blinding
Parents, clinical staff, and all study staff apart from the
research assistants who prepare the study diet will be
blinded to the study group. Blinding will be facilitated by
the use of amber enteral feeding tubes to hide the ap-
pearance of the milk. Unblinding will be permitted if an
error in milk preparation is identified, if a participant ex-
periences growth faltering despite all strategies outlined
in the protocol, or if unexpected safety concerns arise
that require unblinding.
Data collection and management
Most study data will be stored in Research Electronic
Data Capture (REDCap), a secure, HIPAA compliant ap-
plication. Maternal questionnaires will be both adminis-
tered and stored within REDCap. Milk analysis and
PEAPOD data will be downloaded directly from the de-
vices onto flash drives and transferred to a secure shared
server. MRI files will be transferred directly from the
scanner to a research server.
Collection and storage of biological specimens for future
use
We will collect 2 mL of unfortified milk and 1mL of for-
tified milk each time milk is prepared for the study diet
and store it at − 80 °C.
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Statistical methods
Our overall analytic strategy compares pre-specified pri-
mary and secondary outcomes between control and
intervention groups. We will follow the intention-to-
treat principle and analyze data for all enrolled partici-
pants. We will use multiple imputation to address miss-
ing data due to death or loss to follow-up. Results will
be expressed as mean or median differences with 95%
confidence intervals. We will use mixed linear models
adjusted for intrafamilial clustering due to multiple
births, along with control for baseline covariates, as
needed, to minimize effects of between-group differences
in baseline factors due to chance. We will examine inter-
vention effects in the complete cohort and use stratifica-
tion approaches to explore the effects of variables
specified a priori including sex, fetal growth status (SGA
vs. non-SGA), and gestational age (24–27 weeks vs. 28–
30 weeks).
Discussion
Here, we describe the protocol for a randomized, con-
trolled trial of individually targeted human milk fortifica-
tion during the NICU hospitalization for preterm infants
born at 24 to 30 completed weeks’ gestation. We will
measure the effectiveness of this intervention in terms of
1) increasing physical growth and optimizing body com-
position during the NICU hospitalization; 2) improving
structural brain development by term equivalent age;
and 3) improving neurodevelopmental outcomes at 2
years’ corrected age.
Our protocol has several strengths. One is the integra-
tion of our intervention into the NICU workflow. An-
other is our combination of standard and innovative
outcome measures. For example, we will assess not just
standard anthropometry but also infant body compos-
ition, including fat-free mass which indexes muscle and
organ growth. Brain MRI at term equivalent age will en-
able us to detect short-term effects of the nutritional
intervention on brain size and microstructure. At 2
years’ corrected age, measures of working memory and
behavioral inhibition, which reflect emerging executive
function, as well as measures of sustained attention and
self-regulation will complement the standard Bayley
scales. Another strength is the “triple blinding” of par-
ents, clinicians, and study staff to minimize biases that
could affect participant allocation, assessment, and/or
adherence to the intervention. Limitations include the
single-center design, which may reduce generalizability,
and the sample size, which may preclude the detection
of small but clinically important effects. Additionally, the
intervention is labor intensive, with future work needed
to optimize for scalability.
In conclusion, we have designed a randomized con-
trolled trial to test the effectiveness of individually tar-
geted human milk fortification during the NICU
hospitalization. This nutritional intervention during a
critical period in preterm infant brain development has
the potential to improve both short and long-term out-
comes for very preterm infants.
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Fig. 2 Nourish study timeline of enrollment, interventions, and assessment. The study diet will start the first weekday that the infant reaches a full
volume, fortified enteral diet (≥140mL/kg/day human milk). The study diet will end at 36 weeks’ postmenstrual age (PMA). Anthro is
anthropometry (weight, length, head circumference). BC is body composition assessed with air displacement plethysmography. MRI will be
obtained at 38–41 weeks’ PMA. Bayley Scales of Infant and Toddler Development, 4th edition will be used. Spatial working memory will be
assessed with the “Spin the Pots” task, behavioral inhibition with the “Mommies and Babies” task, and executive function and behavioral
difficulties with parent questionnaires (Behavioral Rating Inventory of Executive Function – Preschool Version; and Infant-Toddler Symptom
Checklist—Long Version). Ages in the follow-up phase are corrected ages (age corrected for preterm birth)
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